Defining Neutralization Breadth in HIV+ Human Serum

定义 HIV 人血清中的中和广度

基本信息

  • 批准号:
    7761618
  • 负责人:
  • 金额:
    $ 38.75万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2009
  • 资助国家:
    美国
  • 起止时间:
    2009-09-26 至 2011-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): HIV vaccine strategies have not yet succeeded in generating broadly neutralizing antibody responses in humans. A limited number of broadly neutralizing human monoclonal antibodies against HIV have been identified and have been the subject of intensive study. Combinations of such antibodies can protect macaques from infection with SIV/HIV chimeric virus, suggesting that if they could be elicited in uninfected humans through vaccination, they could provide protective efficacy. These antibodies may be rare in infected humans, however. In contrast, HIV-infected individuals who demonstrate substantial breadth of neutralization in serum are not rare. We hypothesize that a polyspecific response develops during infection in a substantial subset of individuals and accounts for neutralization breadth. The major goal of this proposal is to define the polyspecific response to HIV present in sera from HIV+ individuals with broad neutralizing antibody responses, and to compare the neutralizing antibody specificities with those who demonstrate narrow neutralization breadth. To do this, we will first define the relationship between envelope trimer binding, avidity, and breadth of neutralization using a novel VLP-based assay. We will determine if trimer-specific antibody responses contribute substantially to the breadth of neutralization in polyclonal serum through antibody depletion techniques and epitope mapping. The clonality of the neutralizing antibody response will be determined for broad and narrow neutralizers. Serum analysis will be complemented by the analysis of B cell subsets identified by VLP binding, and phenotypes associated with broad vs. narrow neutralization will be identified. Together, these studies will enlighten our understanding of neutralization breadth and contribute to the design of a neutralizing antibody-based vaccine regimen. It is very likely that an effective HIV vaccine will need to generate neutralizing antibody responses that can prevent infection with the types of HIV that are circulating in the community. It has been very difficult to generate such broad neutralizing responses using standard vaccine techniques. In this project, we will study the antibody responses in individuals who are infected with HIV who have evidence of broad neutralizing responses. By understanding in detail the antibody responses present in these HIV-infected individuals, we will gain insights into how we can better design a protective HIV vaccine that can generate similar responses in uninfected persons.
描述(由申请人提供):艾滋病毒疫苗策略尚未成功地在人类中产生广泛的中和抗体反应。已经确定了数量有限的广泛中和的人类抗艾滋病毒的单抗,并已成为深入研究的主题。这些抗体的组合可以保护猕猴免受SIV/HIV嵌合病毒的感染,这表明如果它们可以通过疫苗在未感染的人类身上诱导,它们可以提供保护效果。然而,这些抗体在受感染的人中可能很少见。相比之下,在血清中表现出大量中和能力的艾滋病毒感染者并不少见。我们假设,在感染过程中,在相当一部分个体中会产生多特异性反应,并解释中和广度。这项建议的主要目的是确定具有广泛中和抗体反应的HIV+个体血清中存在的对HIV的多特异性反应,并比较中和抗体的特异性和那些表现出较窄中和广度的人。要做到这一点,我们首先将使用一种新的基于VLP的分析方法来定义包膜三聚体结合、亲和力和中和广度之间的关系。我们将通过抗体耗竭技术和表位映射来确定三聚体特异性抗体反应是否对多克隆血清中和的广度有实质性贡献。中和抗体反应的克隆性将被确定为广泛和狭义的中和剂。血清分析将由VLP结合确定的B细胞亚群分析补充,并将确定与广泛中和与狭义中和相关的表型。总之,这些研究将启发我们对中和广度的理解,并有助于设计基于中和抗体的疫苗方案。一种有效的艾滋病毒疫苗很可能需要产生中和抗体反应,以防止感染在社区中传播的艾滋病毒类型。使用标准疫苗技术很难产生如此广泛的中和反应。在这个项目中,我们将研究感染艾滋病毒的个体的抗体反应,他们有证据表明有广泛的中和反应。通过详细了解这些艾滋病毒感染者体内存在的抗体反应,我们将深入了解如何更好地设计一种保护性艾滋病毒疫苗,使其能够在未感染的人中产生类似的反应。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

PAUL W. SPEARMAN其他文献

PAUL W. SPEARMAN的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('PAUL W. SPEARMAN', 18)}}的其他基金

Modeling HIV and methamphetamine-induced neuroinflammation in cerebral organoids
模拟 HIV 和甲基苯丙胺诱导的脑类器官神经炎症
  • 批准号:
    10528845
  • 财政年份:
    2022
  • 资助金额:
    $ 38.75万
  • 项目类别:
Role of Siglec-1 in HIV Interactions with Microglia and Astrocytes
Siglec-1 在 HIV 与小胶质细胞和星形胶质细胞相互作用中的作用
  • 批准号:
    10399644
  • 财政年份:
    2020
  • 资助金额:
    $ 38.75万
  • 项目类别:
Role of Siglec-1 in HIV Interactions with Microglia and Astrocytes
Siglec-1 在 HIV 与小胶质细胞和星形胶质细胞相互作用中的作用
  • 批准号:
    10611438
  • 财政年份:
    2020
  • 资助金额:
    $ 38.75万
  • 项目类别:
Role of Siglec-1 in HIV Interactions with Microglia and Astrocytes
Siglec-1 在 HIV 与小胶质细胞和星形胶质细胞相互作用中的作用
  • 批准号:
    10206089
  • 财政年份:
    2020
  • 资助金额:
    $ 38.75万
  • 项目类别:
Role of Siglec-1 in HIV Interactions with Microglia and Astrocytes
Siglec-1 在 HIV 与小胶质细胞和星形胶质细胞相互作用中的作用
  • 批准号:
    10055497
  • 财政年份:
    2020
  • 资助金额:
    $ 38.75万
  • 项目类别:
HIV-Specific B Cell Repertoire in Humans Following Cross-Clade Immunization
跨进化枝免疫后人类 HIV 特异性 B 细胞库
  • 批准号:
    8410925
  • 财政年份:
    2012
  • 资助金额:
    $ 38.75万
  • 项目类别:
HIV-Specific B Cell Repertoire in Humans Following Cross-Clade Immunization
跨进化枝免疫后人类 HIV 特异性 B 细胞库
  • 批准号:
    8500181
  • 财政年份:
    2012
  • 资助金额:
    $ 38.75万
  • 项目类别:
FEI Transmission Electron Microscope with Tomography Capability
具有断层扫描功能的 FEI 透射电子显微镜
  • 批准号:
    7596130
  • 财政年份:
    2009
  • 资助金额:
    $ 38.75万
  • 项目类别:
Defining Neutralization Breadth in HIV+ Human Serum
定义 HIV 人血清中的中和广度
  • 批准号:
    7936231
  • 财政年份:
    2009
  • 资助金额:
    $ 38.75万
  • 项目类别:
Pseudovirion Formation by Live Vector HIV Vaccines
活载体 HIV 疫苗形成假病毒粒子
  • 批准号:
    7244076
  • 财政年份:
    2006
  • 资助金额:
    $ 38.75万
  • 项目类别:

相似海外基金

University of Aberdeen and Vertebrate Antibodies Limited KTP 23_24 R1
阿伯丁大学和脊椎动物抗体有限公司 KTP 23_24 R1
  • 批准号:
    10073243
  • 财政年份:
    2024
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Knowledge Transfer Partnership
Role of Natural Antibodies and B1 cells in Fibroproliferative Lung Disease
天然抗体和 B1 细胞在纤维增生性肺病中的作用
  • 批准号:
    10752129
  • 财政年份:
    2024
  • 资助金额:
    $ 38.75万
  • 项目类别:
CAREER: Next-generation protease inhibitor discovery with chemically diversified antibodies
职业:利用化学多样化的抗体发现下一代蛋白酶抑制剂
  • 批准号:
    2339201
  • 财政年份:
    2024
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Continuing Grant
Isolation and characterisation of monoclonal antibodies for the treatment or prevention of antibiotic resistant Acinetobacter baumannii infections
用于治疗或预防抗生素耐药鲍曼不动杆菌感染的单克隆抗体的分离和表征
  • 批准号:
    MR/Y008693/1
  • 财政年份:
    2024
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Research Grant
Developing first-in-class aggregation-specific antibodies for a severe genetic neurological disease
开发针对严重遗传神经系统疾病的一流聚集特异性抗体
  • 批准号:
    10076445
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Grant for R&D
Discovery of novel nodal antibodies in the central nervous system demyelinating diseases and elucidation of the mechanisms through an optic nerve demyelination model
发现中枢神经系统脱髓鞘疾病中的新型节点抗体并通过视神经脱髓鞘模型阐明其机制
  • 批准号:
    23K14783
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Elucidation of the mechanisms controlling the physicochemical properties and functions of supercharged antibodies and development of their applications
阐明控制超电荷抗体的理化性质和功能的机制及其应用开发
  • 批准号:
    23KJ0394
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
    Grant-in-Aid for JSPS Fellows
Role of antibodies in hepatitis E virus infection
抗体在戊型肝炎病毒感染中的作用
  • 批准号:
    10639161
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Defining the protective or pathologic role of antibodies in Post-Ebola Syndrome
定义抗体在埃博拉后综合症中的保护或病理作用
  • 批准号:
    10752441
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
Human CMV monoclonal antibodies as therapeutics to inhibit virus infection and dissemination
人 CMV 单克隆抗体作为抑制病毒感染和传播的治疗药物
  • 批准号:
    10867639
  • 财政年份:
    2023
  • 资助金额:
    $ 38.75万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了